Second Phase 1 Oncology Trial Further Demonstrates Interleukin-7 Potential To Induce Dramatic And Prolonged CD4 And CD8 T Cell Expansion
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the publication of data from a phase 1 dose escalation study evaluating the effects of IL-7 therapy on human lymphocytes in subjects with non-hematologic, non-lymphoid cancer refractory to standard therapy. The results of this study, performed in collaboration with U.S.
More: continued here
Filed under: Cancer on June 30th, 2008